Clopistad inhibits platelet aggregation by selectively inhibiting the binding of adenosine diphosphate (ADP) to its platelet receptor and inhibits platelet aggregation induced by agonists other than ADP by blocking the amplification of platelet activation by released ADP.

Pack size Box of 30 tablets.
Shelf-life 24 months
Composition Clopidogrel
Dosage forms and strengths Film-coated tablet: 75 mg.
Product code :



Prevention of atherothrombotic events in:

  • Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
  • Adult patients who suffering from acute coronary syndrome with non-ST segment elevation (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement; or patients with ST segment elevation acute myocardial infarction receiving medically treated eligible for thrombolytic therapy.

Prevention of atherothrombotic and thromboembolic events including stroke in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin K antagonists (VKA) and who have a low bleeding risk.


  • Adults and elderly: A single daily dose of 1 tablet.
  • In non-ST segment elevation acute coronary syndrome: Initiate with a single 4-tablet loading dose and then continued at 1 tablet once a day (with aspirin ≤ 100 mg daily).
  • In ST segment elevation acute myocardial infarction: Initiate with a 4-tablet loading dose in combination with aspirin and with or without thrombolytics, for at least 4 weeks, continued at 1 tablet once a day. For patients over 75 years of age, clopidogrel should be initiated without a loading dose.
  • In atrial fibrillation: A single daily dose of 1 tablet in combination with aspirin (75 – 100 mg daily).


Clopistad is administered orally with or without food.

Known hypersensitivity to any of the active substance or excipients.

Presence of active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage).

Severe hepatic impairment.


Gastrointestinal haemorrhage, diarrhoea, abdominal pain, dyspepsia.



Clopistad should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions; patients with renal impairment, moderate hepatic disease who may have bleeding diatheses.

Clopistad cannot be recommended during the first 7 days after acute ischaemic stroke.

Clopistad should be used during pregnancy only if clearly needed. Discontinue nursing or discontinue Clopistad in breastfeeding woman.

Patients should be aware of how they react to drug before driving or operating machinery.